Skip to main content

Table 3 Rate of decline in FEV1, FVC, and FEV1/FVC ratio by GOLD stage

From: The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes

 

GOLD I + II (n = 636)

GOLD III + IV (n = 710)

Rate of decline in FEV1

  

 Annual rate of decline, mL

46

23

 Difference, mL (95 % CI)

23 (9, 38); p = 0.0017

 

Rate of decline in FVC

  

 Annual rate of decline, mL

55

37

 Difference, mL (95 % CI)

18 (−7, 43); p = 0.1658

 

Rate of decline in FEV1/FVC

  

 Annual rate of decline, %

0.51

0.26

 Difference, % (95 % CI)

0.25 (−0.12, 0.62); p = 0.1914

 
  1. Note that rounding of decimals has been applied throughout, including for the difference calculations
  2. Abbreviations: CI confidence interval, FEV 1 forced expiratory volume in 1 second, FVC forced vital capacity, GOLD Global Initiative for Chronic Obstructive Lung Disease